Guojin Securities: First coverage of Connoa-B (02162.HK) with a "buy" rating and a target price of HK $83.29.

According to the news obtained by the Wise Financial APP, Guojin Securities released a research report stating that Kangnaoya-B (02162.HK) has a diversified pipeline, with its core product Simuchibai monoclonal antibody already approved for listing. CM512 (TSLP/IL-13 dual antibody) is currently expanding into multiple phase II clinical trials, and the authorized CMG901 by AZ is expected to submit an NDA in the United States in 2026. Early research layout in multiple technology platforms, the pipeline is expected to advance gradually, and there is sufficient backup force. The first coverage was given a "buy" rating with a target price of HK$83.29.